Telangana DCA Seizes Overpriced ‘ICONE-200’ At Pharmacy In Quthbullapur

Hyderabad: The Drugs Control Administration, Telangana seized antifungal medicine ‘ICONE-200 Capsules’ (Itraconazole Capsules 200 mg) at Quthbullapur Village, Medchal-Malkajgiri district for over-pricing.

According to the DCA officials, the MRP indicated is very high compared to the ceiling price fixed for the product by the central government.

Upon information, the DCA raided a medical shop located in Quthbullapur Village, Medchal-Malkajgiri district on Monday, July 22.

The product Itraconazole Capsules 200 mg sold under the brand name ‘ICONE-200 Capsules’ is under price control as per Drugs (Prices Control) Order, 2013 and the price of the product shall be as per the ‘Ceiling Price’ fixed by National Pharmaceutical Pricing Authority (NPPA), government of India.

The Central government has set the ceiling price for Itraconazole Capsules 200 mg at Rs 22.12 per capsule, based on the Wholesale Price Index (WPI). However, Mascot Health Series Private Limited is selling the product for Rs 441.24 for a pack of 10 capsules, which amounts to Rs 44.12 per capsule. This pricing violates the Drugs (Prices Control) Order, 2013.

Mascot Health Series Private Limited which is marketing the product selling for Rs 441.24 for 10 capsules i.e. Rs. 44.12 per one capsule, on the label of the product which is a violation of Drugs (Prices Control) Order, 2013.

“The firm overpriced the product. The firm charged an excess of Rs 193.5 for 10 capsules,” said DCA officials.

Further investigation will be carried out and action shall be taken as per the law against all the offenders.

Related Posts

Puresta launches EVERQ, AI-powered skin-health platform

Puresta Lifestyle Private Limited announced the launch of EVERQ, an AI-powered skin-health platform designed to bring skin assessment, dermatologist consultations, personalised treatment and ongoing skincare together in one connected journey.…

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell interventions that have not been approved for routine clinical use, including those offered for autism, should not be provided as routine, standard or commercial clinical services, the advisory…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre

US FDA launches expedited IND Pilot, begins accepting applications

US FDA launches expedited IND Pilot, begins accepting applications

PIL in SC seeks time-bound probe, stringent action against fake drug networks

PIL in SC seeks time-bound probe, stringent action against fake drug networks

Ghaziabad: Fake supplement racket busted, 5 held

Ghaziabad: Fake supplement racket busted, 5 held

22 medical stores raided in Hisar, 7 stocked dual-use drugs without records

22 medical stores raided in Hisar, 7 stocked dual-use drugs without records